Grant of Options

RNS Number : 9515A

Synairgen plc

07 June 2021

 

Press Release

Synairgen plc

('Synairgen' or the 'Company')

Grant of options

Southampton, UK - 7 June 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 4 June 2021 the Board of Synairgen granted options ('Options') over 831,725 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.42 per cent. of the Company's issued share capital. 

Following this grant, Synairgen has 9,503,004 options in issue, representing 4.75 per cent. of the Company's issued share capital.

Included in the number of Options granted on 4 June 2021, the following Options were issued to directors:

Director	Options Issued
Richard Marsden	135,626
Dr. Phillip Monk	97,953
John Ward	105,487

Following the issue of the Options, the interests of the directors of the Company at

4 June 2021 are as follows:

Director	Total options	Ordinary shares	Total interest	Percentage holding of fully diluted share capital
Richard Marsden	2,817,576	754,667	3,572,243	1.71%
Dr. Phillip Monk	2,046,535	244,600	2,291,135	1.09%
John Ward	2,262,106	514,907	2,777,013	1.33%
Simon Shaw	-	1,531,239	1,531,239	0.73%
Iain Buchanan	-	112,741	112,741	0.05%
Dr. Bruce Campbell	-	322,830	322,830	0.15%
Prof. Sir Stephen Holgate	-	886,931	886,931	0.42%

In addition, Jody Brookes, Richard Hennings and Victoria Tear, persons disclosing managerial responsibilities, were granted 62,460, 242,568 and 49,968 Options respectively on the same terms as above. The balance of the Options were granted to a number of employees.

The Options are issued under the Company's Long Term Incentive Plans and are exercisable up to 3 June 2031, subject to the achievement of appropriate performance criteria.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')

For further information, please contact:

Synairgen plc  

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Jessica Hodgson, Carina Jurs

[e-mail]

Tel: [phone]

MK Strategies, LLC (US Media Relations)

Mary Conway

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen  

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.

Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com  

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Marsden
2.	Reason for notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	135,626 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	4 June 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Dr Phillip Monk
2.	Reason for notification
a)	Position / status	Chief Scientific Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	97,953 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	4 June 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	John Ward
2.	Reason for notification
a)	Position / status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument  Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	105,487 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	4 June 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Jody Brookes
2.	Reason for notification
a)	Position / status	Head of Clinical Operations
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	62,460 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	4 June 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Victoria Tear
2.	Reason for notification
a)	Position / status	Head of Laboratories
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	49,968 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	4 June 2021
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Hennings
2.	Reason for notification
a)	Position / status	Chief Commercial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	242,568 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	4 June 2021
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHFFMBTMTIMBMB